Chemotherapy DNA CD Protein Inhibitors Immunotherapy BCL Inhibitors Epigenetics Other Tyrosine Kinase Inhibitors Serine-Threonine Kinase Inhibitors Immune Checkpoint Inhibitors Cyclin Dependent Kinase Inhibitors | Acute Myelogenous Leukemia | Leukemia | Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia |
---|---|---|---|---|
cytarabine | ||||
venetoclax | ||||
HAG + azacitidine | ||||
azacitidine | ||||
SNDX-5613 | ||||
cytarabine | ||||
FLAI | ||||
decitabine | ||||
quizartinib | ||||
venetoclax + ruxolitinib | ||||
cytarabine + clofarabine | ||||
cytarabine + cladribine | ||||
decitabine + clofarabine | ||||
decitabine + cladribine | ||||
PD1 inhibitor | ||||
venetoclax + gilteritinib | ||||
ARO-002 | ||||
venetoclax + SNDX-5613 | ||||
JNJ-6617 | ||||
olutasidenib | ||||
cytarabine + idarubicin hydrochloride | ||||
gemtuzumab ozogamicin | ||||
dactinomycin | ||||
GS-9973 | ||||
sorafenib | ||||
KO-539 | ||||
venetoclax + DS-1594 | ||||
cytarabine/daunorubicin liposomal formulation | ||||
ABBV-744 | ||||
venetoclax + IACS-010759 | ||||
EPZ004777 | ||||
NSC348884 | ||||
DS-1594 | ||||
abemaciclib + KO-539 | ||||
KO-539 + OTX015 | ||||
venetoclax + KO-539 | ||||
NSC23766 | ||||
venetoclax + JNJ-6617 | ||||
GS-9876 |